Mahmood I, Li Z
Immunotherapy. 2024; 16(13):879-894.
PMID: 39323402
PMC: 11457669.
DOI: 10.1080/1750743X.2024.2382081.
Liu S, Li Y, Li Z, Wu S, Harrold J, Shah D
J Pharmacokinet Pharmacodyn. 2024; 51(5):449-476.
PMID: 38691205
DOI: 10.1007/s10928-024-09922-x.
Nyesiga B, Levin M, Sall A, Rosen A, Jansson K, Fritzell S
MAbs. 2024; 16(1):2330113.
PMID: 38527972
PMC: 10965115.
DOI: 10.1080/19420862.2024.2330113.
Ulitzka M, Harwardt J, Lipinski B, Tran H, Hock B, Kolmar H
Molecules. 2024; 29(5).
PMID: 38474651
PMC: 10935230.
DOI: 10.3390/molecules29051140.
Amer E, Allam S, Hassan A, El-Fakharany E, Agwa M, Khattab S
PLoS Negl Trop Dis. 2023; 17(12):e0011776.
PMID: 38039267
PMC: 10691730.
DOI: 10.1371/journal.pntd.0011776.
Serum albumin binding knob domains engineered within a V framework III bispecific antibody format and as chimeric peptides.
Adams R, Joyce C, Kuravskiy M, Harrison K, Ahdash Z, Balmforth M
Front Immunol. 2023; 14:1170357.
PMID: 37251411
PMC: 10213618.
DOI: 10.3389/fimmu.2023.1170357.
Resolution of cisplatin-induced fatigue does not require endogenous interleukin-10 in male mice.
Scott K, Boukelmoune N, Taniguchi C, Phillip West A, Heijnen C, Dantzer R
Behav Brain Res. 2023; 444:114381.
PMID: 36870396
PMC: 10029095.
DOI: 10.1016/j.bbr.2023.114381.
Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant .
Singh S, Barbarino A, Youssef E, Coleman D, Gebremariam T, Ibrahim A
J Fungi (Basel). 2023; 9(1).
PMID: 36675924
PMC: 9860579.
DOI: 10.3390/jof9010103.
Is immunotherapy at reduced dose and radiotherapy for older patients with locally advanced non-small lung cancer feasible?-a narrative review by the international geriatric radiotherapy group.
Vinh-Hung V, Gorobets O, Duerinkcx A, Dutta S, Oboite E, Oboite J
Transl Cancer Res. 2022; 11(9):3298-3308.
PMID: 36237270
PMC: 9552052.
DOI: 10.21037/tcr-22-821.
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.
Huang W, Stader F, Chan P, Shemesh C, Chen Y, Gill K
Front Pharmacol. 2022; 13:974423.
PMID: 36225583
PMC: 9548535.
DOI: 10.3389/fphar.2022.974423.
Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency.
Salerno S, Deng R, Kakkar T
CPT Pharmacometrics Syst Pharmacol. 2022; 11(10):1316-1327.
PMID: 35860862
PMC: 9574734.
DOI: 10.1002/psp4.12847.
Minimal residual disease negativity by next-generation flow in non-CR myeloma patients.
Kim S, Yang N, Jeong D, Yun J, Ryu S, Yoon S
EJHaem. 2022; 1(2):563-566.
PMID: 35844993
PMC: 9175670.
DOI: 10.1002/jha2.103.
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains.
Hawkins A, Joyce C, Brady K, Hold A, Smith A, Knight M
MAbs. 2022; 14(1):2076295.
PMID: 35634719
PMC: 9154775.
DOI: 10.1080/19420862.2022.2076295.
High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis.
Hiya S, Fujiwara S, Tanaka F, Kohara N, Kawamoto M
eNeurologicalSci. 2022; 27:100404.
PMID: 35603015
PMC: 9121235.
DOI: 10.1016/j.ensci.2022.100404.
Pharmacogenetics of anticancer monoclonal antibodies.
Shek D, Read S, Ahlenstiel G, Piatkov I
Cancer Drug Resist. 2022; 2(1):69-81.
PMID: 35582142
PMC: 9019180.
DOI: 10.20517/cdr.2018.20.
Development of CAR T Cell Therapy in Children-A Comprehensive Overview.
Boettcher M, Joechner A, Li Z, Yang S, Schlegel P
J Clin Med. 2022; 11(8).
PMID: 35456250
PMC: 9024694.
DOI: 10.3390/jcm11082158.
Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies.
Muliaditan M, Sepp A
Clin Transl Sci. 2022; 15(7):1634-1643.
PMID: 35445800
PMC: 9283736.
DOI: 10.1111/cts.13278.
Intravenous immunoglobulin: A potential treatment for the post-acute sequelae of SARS-Cov-2 infection?.
Reznik S, Tiwari A, Ashby C
Bosn J Basic Med Sci. 2022; 22(4):660-664.
PMID: 35150477
PMC: 9392972.
DOI: 10.17305/bjbms.2021.6901.
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
Maeda K, Amano M, Uemura Y, Tsuchiya K, Matsushima T, Noda K
Sci Rep. 2021; 11(1):22848.
PMID: 34819514
PMC: 8613264.
DOI: 10.1038/s41598-021-01930-y.
Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic.
Lledo-Garcia R, Dixon K, Shock A, Oliver R
CPT Pharmacometrics Syst Pharmacol. 2021; 11(1):116-128.
PMID: 34735735
PMC: 8752106.
DOI: 10.1002/psp4.12739.
